Avtor/Urednik		Borštnar, Simona
Naslov		Napovedni pomen ukrokinaznega aktivatorja plazminogena, njegovih inhibitorjev in receptorja pri raku dojke
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Medicinska fakulteta
Leto izdaje		2003
Obseg		str. 81
Jezik		slo
Abstrakt		The prognosis of cancer is primarlly dependent on its potential to invade and metastasize. Urokinase-type plasminogen activator (uPA), its inhibitors (PAI-Z and PAI-2) and lts receptor (uPAR) all play a key role in tumor invasion and metastasis. The primary endpoint of our study was to evaluate the prognostic impact of PAI-1 and the three other components of the urokinase-type plasminogen ativator sysiem (uPA, PAI-Z and uPAR) as well as their combination in a group of 460 primary breast cancer patients. The secondary endpoint was to evaluate the prognostic impact of these factors in a subgroup of breast cancer patients This study included 460 patients with operable breast cancer, who are treated at the Institute of Oncology between 1997 and 1998. Cytosols and Triton X-ZOO extracts were prepared from the breast cancer tumors immediately after suegery. Content of uPA, PAI-Z and uPAR was measured in tumor extracis while aontent of PAI-2 was measured in tumor cytnsols, using ELISAs. Correlations belween invasive markers and other tumor characteristics were analyzed using Spearman rank correlation (rs) and Mann- Withney test. The optlmized cut-off of uPA, PAI-1, PAI-2 and uPAR was determined. Disease-free survival (DFS) according to all variables was calculated by Kaplan-Meier method, and the differences were assessed with the !og-rank test Univariate and multivariate analyses were performed by applying the Cox proportional hazards model. After a median follow-up of 33 months, 18.5% of the patients relapsed. We demonstrated that PAI-1, as wel! as PAI-2, provide independent prognostic information in breast cancer. Patients with either low values of PAI-1 or high values of PAI-2 were found to have better DFS (RR was 2.67 and 0.58, respectively). (Abstract truncated at 2000 characteristics).
Deskriptorji		BREAST NEOPLASMS UROKINASE PLASMINOGEN ACTIVATOR INHIBITOR 1 PLASMINOGEN ACTIVATOR INHIBITOR 2 PREDICTIVE VALUE OF TESTS PROGNOSIS LYMPHATIC METASTASIS PREMENOPAUSE MENOPAUSE POSTMENOPAUSE NEOPLASM STAGING CHEMOTHERAPY, ADJUVANT ANALYSIS OF VARIANCE MULTIVARIATE ANALYSIS